This Article Abstract Full Text (PDF) All Versions of this Article: 107/5/696    most recent 01.CIR.0000048125.79640.77v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Holmer, S. R. Articles by Schunkert, H. Search for Related Content PubMed PubMed Citation Articles by Holmer, S. R. Articles by Schunkert, H. Related Collections Genetics of cardiovascular disease

(Circulation. 2003;107:696.)
© 2003 American Heart Association, Inc.

Clinical Investigation and Reports

Association of Polymorphisms of the Apolipoprotein(a) Gene With Lipoprotein(a) Levels and Myocardial Infarction

Stephan R. Holmer, MD; Christian Hengstenberg, MD; Hans-Georg Kraft, PhD; Björn Mayer, MD; Melanie Pöll; Susanne Kürzinger; Marcus Fischer, MD; Hannelore Löwel, MD; Gernot Klein, MD; Günter A.J. Riegger, MD; Heribert Schunkert, MD

From the Klinik und Poliklinik für Innere Medizin II, Universität Regensburg (S.R.H., C.H., B.M., M.P., S.K., M.F., G.A.J.R., H.S.), the GSF Forschungszentrum-Institut für Epidemiologie und Sozialmedizin, Neuherberg (H.L.), the Klinik Höhenried für Herz- und Kreislaufkrankheiten, Bernried (G.K.), and the Institut für Medizinische Biologie und Humangenetik, Universität Innsbruck, Austria (H.-G.K).

Correspondence to Prof Dr Stephan Holmer, Klinik und Poliklinik für Innere Medizin II University of Regensburg, 93042 Regensburg, Germany. E-mail stephan.holmer{at}klinik.uni-regensburg.de

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background— Serum lipoprotein(a) [Lp(a)] concentration is largely determined by variability at the apolipoprotein(a) gene locus. Most prominent effects relate to polymorphisms in the promoter (a pentanucleotide [PN] repeat) and coding regions (a kringle IV [K4] repeat), the latter of which also affects Lp(a) particle size. The impact of these polymorphisms on cardiovascular risk is poorly understood.

Methods and Results— We studied both polymorphisms and Lp(a) levels in 834 registry-based myocardial infarction (MI) patients (38% women) and 1548 population-based controls. Lp(a) concentrations were inversely related with the numbers of K4 and PN repeats. However, the effect of the PN polymorphism was restricted to subjects producing small Lp(a) particles (8 PN 66.1 mg/dL versus >8 PN 8.7 mg/dL; P<0.0001). The odds to present with MI were elevated in individuals producing small Lp(a) particles (22 K4 repeats; OR 1.47 for men and 1.69 for women; P<0.002) and in women with 8 PN repeats (OR 1.46, P=0.009). Interestingly, in women, the frequent haplotype with 8 PN and 22 K4 repeats, which is related to high levels of small Lp(a) particles, resulted in an elevated OR for MI (1.79; P=0.01) independently of Lp(a) serum concentration.

Conclusions— The K4 and PN repeat polymorphisms largely explain the high variability of serum Lp(a) levels. A haplotype with 8 PN and 22 K4 repeats is characterized by high concentrations of small Lp(a) particles. Our observation that this haplotype was associated with MI independently of Lp(a) serum levels may suggest that Lp(a) particle size in addition to its concentration may modulate MI risk in women.

Key Words: apolipoproteins • polymorphism • myocardial infarction • women • population

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Lipoprotein(a) [Lp(a)] serum levels have been repeatedly associated with coronary heart disease or myocardial infarction (MI) in large observational studies.^1–7 Interestingly, such associations were found to be particularly prominent in young and middle-aged rather than elderly men⁸ and women.^9,10 Thus, Lp(a) serum levels may modulate the risk for premature arteriosclerosis and MI.

The interindividual variability of Lp(a) levels is very high and is largely determined by the polymorphic apolipoprotein(a) gene on chromosome 6q27.^11–14 The apolipoprotein(a) kringle IV (KIV) repeat polymorphism (38 known alleles) that generates apolipoprotein(a) molecules ranging from 250 to 800 kDa appears to determine about half of the variability of Lp(a) serum levels, with an inverse relationship between the number of KIV repeats and Lp(a) serum concentration.^15,16 However, the variability of Lp(a) concentration is high, particularly in carriers of a low number of KIV repeats, ranging from 0 to >200 mg/dL.^12,16,17 Other polymorphisms in this gene, particularly those located in the 5'-flanking region, were related to serum Lp(a) levels as well, presumably by modulating the transcriptional activity of the apolipoprotein(a) gene.^15–19 A pentanucleotide repeat polymorphism (7 known alleles) at position -1373 from the ATG site may be of particular interest, because a consistent association with Lp(a) levels was found in small populations.^16,19,20 In addition to potential effects on transcriptional activity, this polymorphic site was found to be in linkage disequilibrium with other functional 5'-polymorphisms and with the KIV repeat polymorphism.¹⁶

Despite the evidence for genetic determination of Lp(a) serum levels, data demonstrating linkage or association with coronary artery disease are rare. Some studies have shown association of the KIV polymorphism with coronary artery disease phenotyped by angiography.^21,22 No study has shown linkage or association of any of the Lp(a) polymorphisms with MI. Furthermore, it is not known whether certain haplotypes of the pentanucleotide and the KIV polymorphism are associated with high Lp(a) concentrations or MI. This may be of interest, because such haplotypes may affect both Lp(a) serum concentration and Lp(a) particle size, with potential implications for atherogenicity.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
The Ethics Committee at the University of Regensburg approved the study protocol, and all participants gave informed consent.

Study Populations
Group 1: MI Cases and Controls From the Augsburg MONICA Center
In 1996/1997, MI patients from the population-based MONICA (Multinational Monitoring of Trends and Determinants in Cardiovascular Disease) MI registry Augsburg who had experienced their first MI before 60 years of age were examined in a study center (n=609). MI had been verified according to standard criteria.²³ The control population for this group of MI patients was drawn as a subgroup from the third MONICA survey of the general population of the city of Augsburg in 1994/1995 that originated from a sex/age-stratified cluster sample of all German residents of the Augsburg study area (age 25 to 74 years; participating n=1674).^23–25 All individuals were studied by a standardized interview, clinical examination, and biochemical and molecular analyses.

Group 2: Female MI Cases and Controls From the Regensburg MI Sib-Pair Registry
A second independent case-control population was recruited from cardiovascular rehabilitation centers throughout Germany from 1997 to 2000. A total of 281 female MI patients were examined by a physician at a home visit according to a similar protocol.^25,26 All MI patients had experienced their first MI before 60 years of age and were characterized by a positive family history for coronary heart disease. To serve as a control population for this group of MI patients, 310 nonaffected sisters in-law of MI patients were examined by the identical protocol.

Serum Lipoprotein Levels
Serum for determination of lipoprotein levels was stored at -20°C for up to 3 months before the assay. Serum total cholesterol, LDL cholesterol, and HDL cholesterol were measured by standard enzymatic methods.²⁵ Lp(a) serum concentrations were determined by an Immuno latex-enhanced immunoassay (Immuno AG).

Apolipoprotein(a) KIV Repeat Polymorphism
The number of KIV repeats in the apolipoprotein(a) gene was determined from serum by immunoblotting of SDS-PAGE.^21,22

Apolipoprotein(a) Pentanucleotide Polymorphism
Genotyping of the apolipoprotein(a) pentanucleotide polymorphism was performed after DNA purification by PCR amplification as described by others.¹⁹ Determination of Lp(a) concentration, genotyping of the pentanucleotide polymorphism, and apolipoprotein(a) phenotyping were available in 589 MI patients and 1272 controls from Augsburg, as well as 245 MI patients and 273 controls from Regensburg.

Statistical Analysis
The statistical software package SPSS/PC 10.0 was used. Because of skewness of Lp(a) levels, the nonparametric Mann-Whitney U test was used for comparison of Lp(a) concentrations. Linkage disequilibrium between the pentanucleotide and the KIV polymorphism was determined with the Arlequin (version 2.000) program. Frequencies of genotypes were studied in male and female MI patients and respective sex-matched controls by a ² test. The influence of the KIV and the pentanucleotide polymorphism on the odds of being in the MI group was also calculated in all MI cases and controls in a sex-stratified multiple logistic regression analysis that included risk factors such as age, systolic blood pressure, presence of diabetes mellitus, any history of cigarette smoking, and, in women, menopausal status and estrogen replacement therapy as covariates. To dissect a genetic influence that is present after correction for Lp(a) concentration, all models were performed with or without logarithmically transformed Lp(a) concentration as an independent variable.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Baseline Characteristics
Cardiovascular risk factors were more prevalent in MI patients than in controls (Table 1). The 2 female MI populations showed no relevant differences.

View this table: [in this window] [in a new window]   TABLE 1. Characteristics of MI Patients and Population Controls From Augsburg and Regensburg

Association of Lp(a) Concentration With MI
Lp(a) concentrations were significantly higher in MI patients than in the general population (median in MI patients 16.0 versus 12.1 mg/dL in controls; P<0.0001). The OR for MI in individuals with Lp(a) above a cutoff of 28 mg/dL, which represents the upper quartile of the Lp(a) distribution of the general population, was estimated to be 1.76 (CI 1.36 to 2.26) in men and 2.12 (CI 1.62 to 2.77) in women (P<0.0001).

Association of Apolipoprotein(a) Polymorphisms With Lp(a) Concentration
The KIV repeat and the pentanucleotide repeat polymorphism were found to be in strong linkage disequilibrium (Figure 1; P<0.0001). The allele with 9 pentanucleotide repeats was linked to a high number of KIV repeats, and alleles with 10, 11, or 12 pentanucleotide repeats were found to be linked to small apolipoprotein(a) particles (number of KIV repeats 22). In contrast, homozygous individuals with 8 pentanucleotide repeats, which represents the most frequent genotype (48.2%) of the pentanucleotide repeat polymorphism, showed no apparent linkage with a particular range of KIV repeats.

View larger version (37K): [in this window] [in a new window]   Figure 1. Left, Frequency distribution of dominant KIV allele is depicted in all individuals of this study (top), as well as in homozygous carriers of 8, 9, and 10 pentanucleotide repeats (PNR). Right, Median Lp(a) concentrations are displayed after dichotomized stratification by dominant allele of KIV polymorphism for all individuals, as well as each group of pentanucleotide genotypes. Figure indicates strong linkage disequilibrium of KIV repeat and PNR polymorphism (left), as well as largely differing Lp(a) concentrations, depending on particular haplotypes (right).

Median Lp(a) concentrations were calculated for respective haplotypes (Figure 1). Interestingly, in the group with a low number of KIV repeats, Lp(a) concentrations were largely modulated by the number of pentanucleotide repeats. Haplotypes with 22 KIV repeats and 8 pentanucleotide repeats were associated with particularly high concentrations of small Lp(a) particles. By contrast, in carriers of a high number of KIV repeats that express large Lp(a) particles, the pentanucleotide repeat polymorphism had no relevant influence on Lp(a) concentration. Analysis of all pentanucleotide repeat genotypes stratified by sex and by the number of KIV repeats revealed that individuals with 22 KIV repeats and 8 pentanucleotide repeats showed the highest Lp(a) concentration (Table 2).

View this table: [in this window] [in a new window]   TABLE 2. Median Lp(a) Concentration and Interquartile Range Stratified by KIV Repeat and Pentanucleotide Repeat Polymorphisms

Association of Apolipoprotein(a) Polymorphisms With MI
The detailed distribution of all alleles in controls and MI patients is shown in Figure 2A. A low number of KIV repeats (22) in the dominant allele that was found by Western blot analysis to have the most influence on Lp(a) concentration was more frequently found in male and female patients with MI than in controls (OR 1.470 and 1.687 versus >22 repeats; P=0.002 and <0.0001, respectively).

View larger version (22K): [in this window] [in a new window]   Figure 2. Frequency distribution (percent) of all genotypes of (A) KIV and (B) pentanucleotide repeat polymorphism (PNR) in male and female controls (open bars) and MI patients (shaded bars).

No difference in genotype distribution of the pentanucleotide polymorphism was detected between male MI patients and controls (Figure 2B). In contrast, in women, homozygous carriers of 8 pentanucleotide repeats were more frequently found in the group of MI patients than in the controls (55.3% versus 46.3%; Figure 2B). For further analysis, genotypes that had been associated with the highest Lp(a) concentration (6/8, 7/7, 7/8, and 8/8) were combined into 1 group versus all other genotypes. Individual analyses of case-control populations from Augsburg and Regensburg showed similar genotype distributions and revealed significant associations of these genotypes with MI in both female study groups (Figure 3). Importantly, the association of the pentanucleotide polymorphism with MI was restricted to those women who carried a low number of KIV repeats (Figure 3).

View larger version (23K): [in this window] [in a new window]   Figure 3. ORs and CIs from 2 test in carriers of 8 or fewer pentanucleotide repeats (PNR) compared with carriers of other genotypes. In addition, absolute numbers of cases and controls and frequencies of 8 or fewer PNRs are given. Study groups were further stratified by dominant allele of KIV polymorphism (22 or >22 KIV repeats) to evaluate whether effect of PNR polymorphism was dependent on KIV polymorphism. *Controls were matched for study population and KIV polymorphism.

Multiple regression analyses were performed that adjusted for other risk factors and, in a stepwise fashion, for Lp(a) concentration. These analyses confirmed the significant association of the KIV repeat polymorphism with MI both in men and in women (Figure 4). However, adjustment for Lp(a) concentration abolished this relationship. In contrast, 8 pentanucleotide repeats were independently associated with MI in women even after controlling for Lp(a) serum concentration. Haplotypes with 22 KIV repeats and 8 pentanucleotide repeats that were associated with the highest Lp(a) concentrations showed the highest odds ratios for MI (Figure 4). Although a significant association was abolished by further adjustment for Lp(a) concentration in men, it persisted in women.

View larger version (24K): [in this window] [in a new window]   Figure 4. Adjusted OR from logistic regression analyses with MI status as dependent variable. Models included diabetes mellitus, smoking, age, and, in women, menopausal status and hormone intake as obligate covariates together with respective polymorphism: 22 KIV repeats vs >22 KIV repeats, 8 or fewer pentanucleotide repeats (PNRs) vs >8 PNRs, and 22 KIV repeats combined with 8 or fewer PNRs vs other genotypes. Effect of each polymorphism or haplotype of both was calculated without and with further adjustment for Lp(a) concentration. corr. indicates corrected.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The present investigation evaluated 2 features of the apolipoprotein(a) gene locus that appear to affect Lp(a) plasma concentrations and, potentially, the risk of MI. First, individuals with 22 KIV repeats were found to present with elevated Lp(a) levels²⁷ and an elevated risk for MI. Our observation of a significant association between the KIV repeat polymorphism with MI in both men and women is consistent with many previous studies that reported an association between elevated serum Lp(a) levels and coronary heart disease.^{3,8–10,28–30}

The second feature of the apolipoprotein(a) gene that might affect the risk of MI is the pentanucleotide repeat polymorphism in the promoter region. Although previous analyses demonstrated a significant, albeit moderate effect of this polymorphism on Lp(a) concentration in general,^16,19,20 the present study demonstrated a strong influence of the pentanucleotide polymorphism, specifically in individuals who have low numbers of KIV repeats. Consequently, the pentanucleotide repeat polymorphism appears to determine the number of small Lp(a) particles. The distribution of the KIV and the pentanucleotide polymorphism does not occur at random but is confined to a highly significant linkage disequilibrium. Interestingly, one of the frequently found haplotypes with 22 KIV repeats and 8 pentanucleotide repeats was identified to result in extremely high serum concentrations of small Lp(a) particles.

With respect to MI, it may therefore be of no surprise that this haplotype with 22 KIV repeats and 8 pentanucleotides was related to an elevated risk of MI. However, it may be rather surprising that this association persisted in women after inclusion of Lp(a) serum concentrations in the logistic regression model. Caution is warranted in the interpretation of such statistical evaluations. However, it may be tempting to speculate that large numbers of small Lp(a) particles may confer a specific risk, as has been shown for the quantity and particle size of LDL and HDL cholesterol.^31,32 Indeed, a recent report specifically associated small Lp(a) molecules with poor endogenous fibrinolytic activity.³³ If our finding is reproducible in additional studies, it appears that in women, knowledge of a specific haplotype that produces large amounts of small Lp(a) particles provides predictive information beyond serum Lp(a) concentration.

Given that the association between the 22 KIV/8 pentanucleotide repeats haplotype with MI was significant only in women, one might speculate that Lp(a) may have a greater impact on cardiovascular risk in women than in men. The association of high Lp(a) levels with coronary atherosclerosis and acute coronary events appears to be more pronounced in women than in men in the present study and in a number of previous reports.^9,10,34

A limitation of the present study may be the rather arbitrary grouping of genotypes based on the number of KIV and pentanucleotide repeats, although similar distinctions have been used previously.^4,28 In addition, dichotomized stratification by the number of KIV repeats may result in an underadjustment of the possible confounding effect of the KIV polymorphism. A further limitation of the study is its retrospective character. In particular, we cannot exclude that mortality after the acute MI was different in the respective genotype groups. However, age at time of MI and the time of follow-up after MI were similar in the respective genotype groups, and genotype distribution was not dependent on age (data not shown). Thus, we have no indication of selection bias due to mortality.

In summary, the present study suggests that at least 3 factors affect the association between lipoprotein(a) and the risk of MI. First, the KIV polymorphism is related to MI in both men and women, probably owing to modulation of both Lp(a) concentration and particle size. Second, a pentanucleotide polymorphism significantly affects the risk of MI in women only, which suggests a sex-specific modulation of the risk increase due to elevated Lp(a) particles. Third, a specific and frequent haplotype (22 KIV repeats and 8 pentanucleotide repeats) is associated with MI in women after correction for Lp(a) concentrations. This finding indicates that this particular haplotype, which results in high concentrations of small Lp(a) particles, may confer a specifically high risk that is not entirely reflected by conventional measurement of serum Lp(a) concentration.

	Acknowledgments

 
This study was supported by the Deutsche Forschungsgemeinschaft (DFG Schu672/9-1, Schu672/10-1, Schu672/12-1, and Ho1073/8-1), the BMBF (Dr Löwel, FKZ 01ER9502/0; Dr Schunkert, KBF-FKZ 01GB9403), the Ernst-und Berta-Grimmke-Stiftung (Drs Hengstenberg and Schunkert), the Wilhelm-Vaillant-Stiftung (Drs Hengstenberg, Schunkert, and Holmer), and the Deutsche Stiftung für Herzforschung (Drs Hengstenberg and Schunkert), as well as BMW AG and Smith Kline Beecham Pharma. We appreciate support from the KORA field study team in Augsburg, the Regensburg MI sib-pair registry team, and 15 German cardiac rehabilitation centers.

Received August 6, 2002; revision received October 25, 2002; accepted October 28, 2002.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Danesh J, Collins R, Peto R, et al. Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies. Circulation. 2000; 102: 1082–1085.[Abstract/Free Full Text]

2. Marcovina SM, Albers JJ, Wijsman E, et al. Differences in Lp[a] concentrations and apo[a] polymorphisms between black and white Americans. J Lipid Res. 1996; 37: 2569–2585.[Abstract]

3. Nguyen TT, Ellefson RD, Hodge DO, et al. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation. 1997; 96: 1390–1397.[Abstract/Free Full Text]

4. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol. 1997; 17: 239–245.[Abstract/Free Full Text]

5. Berg K, Dahlen G, Christophersen B, et al. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet. 1997; 52: 254–261.[Medline] [Order article via Infotrieve]

6. Cremer P, Nagel D, Mann H, et al. Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS), I: risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis. 1997; 129: 221–230.[CrossRef][Medline] [Order article via Infotrieve]

7. Assmann G, Schulte H, Von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 1996; 77: 1179–1184.[CrossRef][Medline] [Order article via Infotrieve]

8. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA. 1996; 276: 544–548.[Abstract/Free Full Text]

9. Orth-Gomer K, Mittleman MA, Schenck-Gustafsson K, et al. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation. 1997; 95: 329–334.[Abstract/Free Full Text]

10. Dahlen GH, Srinivasan SR, Stenlund H, et al. The importance of serum lipoprotein (a) as an independent risk factor for premature coronary artery disease in middle-aged black and white women from the United States. J Intern Med. 1998; 244: 417–424.[CrossRef][Medline] [Order article via Infotrieve]

11. Lackner C, Cohen JC, Hobbs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet. 1993; 2: 933–940.[Abstract/Free Full Text]

12. Sandholzer C, Hallman DM, Saha N, et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991; 86: 607–614.[Medline] [Order article via Infotrieve]

13. Utermann G. Genetic architecture and evolution of the lipoprotein(a) trait. Curr Opin Lipidol. 1999; 10: 133–141.[CrossRef][Medline] [Order article via Infotrieve]

14. Broeckel U, Hengstenberg C, Mayer B, et al. A comprehensive linkage analysis for myocardial infarction and its related risk factors. Nat Genet. 2002; 30: 210–214.[CrossRef][Medline] [Order article via Infotrieve]

15. Kraft HG, Windegger M, Menzel HJ, et al. Significant impact of the +93 C/T polymorphism in the apolipoprotein(a) gene on Lp(a) concentrations in Africans but not in Caucasians: confounding effect of linkage disequilibrium. Hum Mol Genet. 1998; 7: 257–264.[Abstract/Free Full Text]

16. Rosby O, Berg K. LPA gene: interaction between the apolipoprotein(a) size ("kringle IV" repeat) polymorphism and a pentanucleotide repeat polymorphism influences Lp(a) lipoprotein level. J Intern Med. 2000; 247: 139–152.[CrossRef][Medline] [Order article via Infotrieve]

17. Mooser V, Mancini FP, Bopp S, et al. Sequence polymorphisms in the apo(a) gene associated with specific levels of Lp(a) in plasma. Hum Mol Genet. 1995; 4: 173–181.[Abstract/Free Full Text]

18. Suzuki K, Kuriyama M, Saito T, et al. Plasma lipoprotein(a) levels and expression of the apolipoprotein(a) gene are dependent on the nucleotide polymorphisms in its 5'-flanking region. J Clin Invest. 1997; 99: 1361–1366.[Medline] [Order article via Infotrieve]

19. Trommsdorff M, Kochl S, Lingenhel A, et al. A pentanucleotide repeat polymorphism in the 5' control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians. J Clin Invest. 1995; 96: 150–157.[Medline] [Order article via Infotrieve]

20. Amemiya H, Arinami T, Kikuchi S, et al. Apolipoprotein(a) and pentanucleotide repeat polymorphisms are associated with the degree of atherosclerosis in coronary heart disease. Atherosclerosis. 1996; 123: 181–191.[CrossRef][Medline] [Order article via Infotrieve]

21. Sandholzer C, Boerwinkle E, Saha N, et al. Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest. 1992; 89: 1040–1046.[Medline] [Order article via Infotrieve]

22. Kraft HG, Lingenhel A, Pang RW, et al. Frequency distributions of apolipoprotein(a) kringle IV repeat alleles and their effects on lipoprotein(a) levels in Caucasian, Asian, and African populations: the distribution of null alleles is non-random. Eur J Hum Genet. 1996; 4: 74–87.[Medline] [Order article via Infotrieve]

23. Löwel H, Lewis M, Hormann A, et al. Case finding, data quality aspects and comparability of myocardial infarction registers: results of a south German register study. J Clin Epidemiol. 1991; 44: 249–260.[CrossRef][Medline] [Order article via Infotrieve]

24. Muscholl MW, Hense HW, Bröckel U, et al. Changes in left ventricular structure and function in patients with white coat hypertension: cross sectional survey. BMJ. 1998; 317: 565–570.[Abstract/Free Full Text]

25. Holmer SR, Hengstenberg C, Mayer B, et al. Lipoprotein lipase gene polymorphism, cholesterol subfractions and myocardial infarction in large samples of the general population. Cardiovasc Res. 2000; 47: 806–812.[Abstract/Free Full Text]

26. Hengstenberg C, Holmer SR, Mayer B, et al. Evaluation of the aldosterone synthase (CYP11B2) gene polymorphism in patients with myocardial infarction. Hypertension. 2000; 35: 704–709.[Abstract/Free Full Text]

27. Gavish D, Azrolan N, Breslow JL. Plasma Lp(a) concentration is inversely correlated with the ratio of kringle IV/kringle V encoding domains in the apo(a) gene. J Clin Invest. 1989; 84: 2021–2027.[Medline] [Order article via Infotrieve]

28. Brazier L, Tiret L, Luc G, et al. Sequence polymorphisms in the apolipoprotein(a) gene and their association with lipoprotein(a) levels and myocardial infarction: the ECTIM study. Atherosclerosis. 1999; 144: 323–333.[CrossRef][Medline] [Order article via Infotrieve]

29. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993; 270: 2195–2199.[Abstract/Free Full Text]

30. Coleman MP, Key TJ, Wang DY, et al. A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women. Atherosclerosis. 1992; 92: 177–185.[CrossRef][Medline] [Order article via Infotrieve]

31. Packard C, Caslake M, Shepherd J. The role of small, dense low density lipoprotein (LDL): a new look. Int J Cardiol. 2000; 74 (suppl 1): S17–S22.[CrossRef]

32. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation. 1997; 95: 69–75.[Abstract/Free Full Text]

33. Falco C, Estelles A, Dalmau J, et al. Influence of lipoprotein (a) levels and isoforms on fibrinolytic activity: study in families with high lipoprotein (a) levels. Thromb Haemost. 1998; 79: 818–823.[Medline] [Order article via Infotrieve]

34. Bostom AG, Gagnon DR, Cupples LA, et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women: the Framingham Heart Study. Circulation. 1994; 90: 1688–1695.[Abstract/Free Full Text]

This article has been cited by other articles:

				P. R. Kamstrup, A. Tybjaerg-Hansen, R. Steffensen, and B. G. Nordestgaard Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction JAMA, June 10, 2009; 301(22): 2331 - 2339. [Abstract] [Full Text] [PDF]

				H. Schunkert, A. Gotz, P. Braund, R. McGinnis, D.-A. Tregouet, M. Mangino, P. Linsel-Nitschke, F. Cambien, C. Hengstenberg, K. Stark, et al. Repeated Replication and a Prospective Meta-Analysis of the Association Between Chromosome 9p21.3 and Coronary Artery Disease Circulation, April 1, 2008; 117(13): 1675 - 1684. [Abstract] [Full Text] [PDF]

				J. Rubin, H. J. Kim, T. A. Pearson, S. Holleran, R. Ramakrishnan, and L. Berglund Apo[a] size and PNR explain African American-Caucasian differences in allele-specific apo[a] levels for small but not large apo[a] J. Lipid Res., May 1, 2006; 47(5): 982 - 989. [Abstract] [Full Text] [PDF]

				L. Berglund and R. Ramakrishnan Lipoprotein(a): An Elusive Cardiovascular Risk Factor Arterioscler. Thromb. Vasc. Biol., December 1, 2004; 24(12): 2219 - 2226. [Abstract] [Full Text] [PDF]

				A. J. Lusis, A. M. Fogelman, and G. C. Fonarow Genetic Basis of Atherosclerosis: Part II: Clinical Implications Circulation, October 5, 2004; 110(14): 2066 - 2071. [Full Text] [PDF]

				N. Rifai, J. Ma, F. M. Sacks, P. M. Ridker, W. J. L. Hernandez, M. J. Stampfer, and S. M. Marcovina Apolipoprotein(a) Size and Lipoprotein(a) Concentration and Future Risk of Angina Pectoris with Evidence of Severe Coronary Atherosclerosis in Men: The Physicians' Health Study Clin. Chem., August 1, 2004; 50(8): 1364 - 1371. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 107/5/696    most recent 01.CIR.0000048125.79640.77v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Holmer, S. R. Articles by Schunkert, H. Search for Related Content PubMed PubMed Citation Articles by Holmer, S. R. Articles by Schunkert, H. Related Collections Genetics of cardiovascular disease